Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
Deutsche Version Deutsche Version
  MedUni Vienna    Intranet    MedUni Vienna - Shop    University Library    University Hospital Vienna  
 
Krebsforschung_EN.png
 
 
 
Hauptnavigation
  • Home
  • General Information
    • History
    • 50 years Institute for Cancer Research
    • Imagevideo: Institute for Cancer Research
  • Research
    • Research Focus
    • Research Laboratories
    • Scientific Services - Core Facilities
  • Teaching
    • Lectures of the Institute of Cancer Research
    • University Course Toxicology for Postgraduates
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Program Malignant Diseases
    • PhD Program Clinical and Experimental Oncology
  • Contact
    • Contact
    • Map
 
Research / Research Focus / Applied and Experimental Oncology / Hedwig Sutterlüty
 
Subnavigation
  • Research Focus
    • Cellular and Molecular Tumorbiology
    • Applied and Experimental Oncology
      • Walter Berger
      • Martin Filipits
      • Petra Heffeter
      • Michael Grusch
      • Klaus Holzmann
      • Hedwig Sutterlüty
        • Research Projects
        • Group Members
        • Former Group Members
    • Chemical Safety and Cancer Prevention
    • Tumor Progression and Metastasis
  • Research Laboratories
  • Scientific Services - Core Facilities


Inhaltsbereich

 

Hedwig Sutterlüty, Assoc. Prof. Priv.-Doz. Mag.
Group Leader
E-Mail: hedwig.sutterluety [at] meduniwien [dot] ac [dot] at
Phone.: +43 (0)1 40160 - 57526
Fax: +43 (0)1 40160 - 957500

Research Focus

We are interested in three major topics:

  1. Molecular analysis of signal transduction pathways involved in regulation of normal and tumour cells;
  2. Characterisation of mechanisms involved in intracellular regulation of cell proliferation;
  3. Investigations analyzing the role of micro RNAs as important modulator of gene expression in cancer.

 
Group Members

Videos

Selected Publications

MicroRNA-21 Increases Proliferation and Cisplatin Sensitivity of Osteosarcoma-Derived Cells.
Vanas V, Haigl B, Stockhammer V, Sutterluty-Fall H.
PLoS One. 2016 Aug 11;11(8):e0161023. doi: 10.1371/journal.pone.0161023. eCollection 2016.

Differential Effects of Variations at Codon 106 on Sprouty2 Functions in Lung Cancer-Derived Cells.
Kral R, Doriguzzi A, Mayer CE, Krenbek D, Setinek U, Sutterluty-Fall H.
J Cell Biochem. 2016 Aug;117(8):1822-32. doi: 10.1002/jcb.25482. Epub 2016 Jan 21.

The increased Sprouty4 expression in response to serum is transcriptionally
controlled by Specific protein 1

Doriguzzi A, Haigl B, Gsur A, Sutterlüty-Fall H.
Int J Biochem Cell Biol. 2015 Jul;64:220-8. doi: 10.1016/j.biocel.2015.04.017. Epub 2015 May 6.

Expression of microRNA-21 in non-small cell lung cancer tissue increases with disease progression and is likely caused by growth conditional changes during malignant transformation.
Haigl B, Vanas V, Setinek U, Hegedus B, Gsur A, Sutterluty-Fall H.
Int J Oncol. 2014 Apr;44(4):1325-34. doi: 10.3892/ijo.2014.2272. Epub 2014 Jan 22.

Sprouty2 but not Sprouty4 is a potent inhibitor of cell proliferation and migration of osteosarcoma cells.
Rathmanner N, Haigl B, Vanas V, Doriguzzi A, Gsur A, Sutterluty-Fall H.
FEBS Lett. 2013 Aug 19;587(16):2597-605. doi: 10.1016/j.febslet.2013.06.040. Epub 2013 Jul 4.

 

 

All Publications:

PubmedDatabase (Sutterluty)
PubmedDatabase (Sutterluty-Fall)

 
Print
 
 
© MedUni Wien | Publishing information | Terms of use | Data Protection | Accessibility | Contact